<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03484273</url>
  </required_header>
  <id_info>
    <org_study_id>REB17-2393</org_study_id>
    <nct_id>NCT03484273</nct_id>
  </id_info>
  <brief_title>Hemodynamic Effects of Compression in POTS</brief_title>
  <official_title>Body Compression in Postural Tachycardia Syndrome (POTS): Effects on Orthostatic Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      When an individual with Postural Tachycardia Syndrome (POTS) stands up, their heart rate&#xD;
      increases significantly (&gt;30BPM) and they may experience symptoms such as lightheadedness,&#xD;
      dizziness, shortness of breath, nausea and mental confusion.&#xD;
&#xD;
      One commonly prescribed treatment for POTS is compression garments. Compression garments&#xD;
      squeeze veins to help return blood back to the heart, which may decrease heart rate and&#xD;
      symptoms on standing. However, there is little research about the effectiveness of&#xD;
      compression in adults with POTS.&#xD;
&#xD;
      In this study, the investigators will use the Lifewrap garment, which compresses the abdomen,&#xD;
      pelvis and lower extremities, to evaluate the effectiveness of compression in POTS. The&#xD;
      investigators will use a head up tilt (HUT) which will simulate standing. The study&#xD;
      participant will participate in 4x 10 minute HUTs wearing 4 different compression&#xD;
      configurations:&#xD;
&#xD;
        1. full abdomen and lower extremity compression&#xD;
&#xD;
        2. abdominal only compression&#xD;
&#xD;
        3. leg only compression&#xD;
&#xD;
        4. No compression&#xD;
&#xD;
      The investigators hypothesize that with full compression, the participant's heart rate&#xD;
      increase from lying down to upright will be lower than when they are not wearing any&#xD;
      compression. The investigators will also ask the participant about their symptoms when they&#xD;
      are upright.&#xD;
&#xD;
      The results of this study could demonstrate the potential benefits of compression and what&#xD;
      configuration is most effective. These findings could rapidly translate to the clinical&#xD;
      setting, providing improved care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postural Tachycardia Syndrome (POTS) is a chronic form of orthostatic intolerance marked by a&#xD;
      significant and sustained increase in heart rate (HR) upon positional change from supine to&#xD;
      standing (&gt;30 beats/min [bpm]) in the absence of orthostatic hypotension (&lt;20/10 mmHg&#xD;
      decrease). Symptoms must be present for &gt;6 months and other causes of orthostatic tachycardia&#xD;
      must be ruled out. Individuals with POTS report orthostatic symptoms including palpitations,&#xD;
      lightheadedness, and mental clouding, which improve on recumbence. The vast majority of&#xD;
      individuals diagnosed with POTS are women age 13-50 years.&#xD;
&#xD;
      Upon standing, approximately 500 mL of blood immediately redistributes from the thorax down&#xD;
      to the abdomen, buttocks and legs. This leads to sympathetic activation as the baroreceptors&#xD;
      sense less pressure. In a healthy individual, HR initially increases 10-20 bpm, and the&#xD;
      systolic blood pressure (BP) decreases by approximately 5 mmHg. However, in an individual&#xD;
      with POTS, this compensatory mechanism is impaired and HR will increase by &gt;30 bpm and remain&#xD;
      at this elevated rate for the duration of standing. In some individuals with POTS, upon&#xD;
      standing cerebral blood flow velocity decreases. In other individuals, oscillation of&#xD;
      cerebral blood flow due to failure of cerebral autoregulatory mechanisms is observed.&#xD;
&#xD;
      Current treatment of POTS involves pharmacological and non-pharmacological intervention&#xD;
      including salt and fluid loading, exercise, and physical countermanuevers. There are no&#xD;
      approved medications for use in POTS and all use is off label. Compression garments are also&#xD;
      often prescribed. Abdominal/lower extremity compression garments provide pressure to the&#xD;
      blood vessels in the legs, thighs and abdomen which can minimize blood pooling and lead to&#xD;
      improved blood return to the heart. One such garment is the Lifewrap Non-pneumatic AntiShock&#xD;
      garment (NASG), indicated in post-partum hypovolemia.&#xD;
&#xD;
      A pediatric study (n=20) found that orthostatic tachycardia and symptoms were decreased&#xD;
      during head up tilt (HUT), with the use of a different NASG compression garment vs. no&#xD;
      compression. However, there is no data to validate the efficacy of compression in adults&#xD;
      POTS, and also no data to determine which type of compression is most beneficial (e.g. lower&#xD;
      leg only, abdomen only, combination).&#xD;
&#xD;
      The investigators hypothesize that the use of the Lifewrap NASG compression garment in a&#xD;
      fully applied configuration will decrease orthostatic tachycardia and orthostatic symptoms&#xD;
      during a 10 minute HUT vs. no compression garment. The investigators will complete a 4-way&#xD;
      randomized crossover study of HUTs with compression applied by the LifeWrap NSAG in at&#xD;
      attempt to demonstrate decreased orthostatic tachycardia and increased orthostatic tolerance&#xD;
      in individuals with POTS. If successful, this study could provide needed evidence that&#xD;
      compression in POTS is a successful non-pharmacological treatment modality, and as well, what&#xD;
      type of compression is the most beneficial to patients with this syndrome. These findings&#xD;
      could rapidly translate to the clinical setting and improve patient care.&#xD;
&#xD;
      The study participant will complete 4x 10min HUTs during a single study day. There will be 4&#xD;
      compression conditions based on strap configuration of the Lifewrap garment: (1) full&#xD;
      abdominal and lower extremity compression, (2) abdominal only compression, (3) lower&#xD;
      extremity only compression and (4) no compression. A pressure sensor will used to measure the&#xD;
      magnitude of compression pressure applied. The study will be conducted on a tilt table in a&#xD;
      human physiology research and procedure room. Each intervention phase in the protocol will&#xD;
      involve a supine baseline assessment period of 10 minutes followed by a 10 min HUT (80&#xD;
      degrees). There will be a 20 min recovery periods between each HUT. The study will take&#xD;
      approximately 4 hours.&#xD;
&#xD;
      The study participant will be instrumented in a fasting state and on an empty bladder. The&#xD;
      investigators will apply skin electrodes to continuously monitor heart rate and record an&#xD;
      ECG. BP will be monitored continuously using a finger volume clamp method (Nexfin, Edwards&#xD;
      Lifesciences) and calibrated with intermittent brachial cuff measurements (Vital-Guard 450C&#xD;
      Patient Care Monitor, IVY Medical). From the continuous BP waveform, the investigators can&#xD;
      obtain an estimate of stroke volume, cardiac output, and systemic vascular resistance&#xD;
      (Modelflow). Middle cerebral blood flow velocity will be assessed using transcranial doppler.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Actual">January 26, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>There will be 4 compression conditions based on strap configuration of the Lifewrap garment: full abdominal and lower extremity compression, abdominal only compression, lower extremity only compression and no compression. The order of these interventions will be randomized.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Orthostatic Heart Rate (HR) Change</measure>
    <time_frame>Maximum HR between 5-10min HUT MINUS the baseline (pre-tilt) HR</time_frame>
    <description>The primary outcome measure will be the magnitude of HR change from supine to HUT (max HR between 5-10 min of HUT) for each study arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Upright Heart Rate</measure>
    <time_frame>During minutes 5-10 of the HUT</time_frame>
    <description>The maximum heart rate during minutes 5-10 of each HUT. The maximum heart rate during each of the study arms will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Vanderbilt Orthostatic Symptom Score (VOSS) Symptom Rating</measure>
    <time_frame>After t=10 of the 10min HUT (or sooner if HUT has to be terminated early due to symptoms)</time_frame>
    <description>Subjective symptom scoring as reported by participant during each study arm. The VOSS evaluates 9 symptoms on a 0 to 10 scale with 0 being no symptom to 10 being worst ever symptom. The total score ranges from 0-90, with a higher score being more severe symptoms.&#xD;
The 9 symptoms are mental clouding, blurred vision, shortness of breath, rapid heartbeat, tremulousness, chest discomfort, headache, lightheadedness, and nausea. The participant's VOSS score will be compared across the 4 arms of this study.&#xD;
The VOSS score has been previously used in multiple publications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure (SBP)</measure>
    <time_frame>During the baseline before the HUT and the SBP correlating with the maximum HR during 5-10 min HUT, recorded at 1 min intervals.</time_frame>
    <description>Change in continuous systolic blood pressure between supine and HUT during each study arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Stroke Volume</measure>
    <time_frame>During the baseline before the HUT and the SV correlating with the maximum HR during 5-10 min HUT, recorded at 1 min intervals.</time_frame>
    <description>Change in Stroke Volume from supine to HUT in each of the study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Output (CO)</measure>
    <time_frame>During the baseline before the HUT and the CO correlating with the maximum HR during 5-10 min HUT, recorded at 1 min intervals.</time_frame>
    <description>Change in Cardiac Output from supine to HUT in each of the study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic Vascular Resistance (SVR)</measure>
    <time_frame>During the baseline before the HUT and the SVRcorrelating with the maximum HR during 5-10 min HUT, recorded at 1min intervals.</time_frame>
    <description>Change in Systemic Vascular Resistance from supine to HUT in each of the study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cerebral Blood Flow Velocity (CBFV)</measure>
    <time_frame>During the baseline before the HUT and the CBFV correlating with the maximum HR during 5-10 min HUT, recorded at 1 min intervals.</time_frame>
    <description>Change in cerebral blood flow from supine to HUT in each of the study arms.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Postural Tachycardia Syndrome</condition>
  <arm_group>
    <arm_group_label>Full Compression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The LifeWrap compression garment will be fully secured with all straps.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abdominal and Pelvic Compression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower Limb Compression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Lifewrap compression garment calf and ankle straps only will be secured.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Compression</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>None of the LifeWrap compression garment straps will be secured.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LifeWrap Compression Garment</intervention_name>
    <description>Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
    <arm_group_label>Abdominal and Pelvic Compression</arm_group_label>
    <arm_group_label>Full Compression</arm_group_label>
    <arm_group_label>Lower Limb Compression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Physician diagnosis of Postural Tachycardia Syndrome (POTS)&#xD;
&#xD;
          -  Age 18-60 years (we are an adult group and we do not see pediatric patients clinically&#xD;
             and do not have appropriate pediatric expertise)&#xD;
&#xD;
          -  Male and Female&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
          -  Ability to travel to Libin Cardiovascular Institute of Alberta Autonomic Testing Lab&#xD;
             at the University of Calgary, Calgary, AB.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Overt cause for postural tachycardia, i.e., acute dehydration&#xD;
&#xD;
          -  Participants with somatization or severe anxiety symptoms will be excluded (as they&#xD;
             may not tolerated study procedures)&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Inability to tolerate compression garment for the duration of the study&#xD;
&#xD;
          -  Other factors which in the investigator's opinion would prevent the participant from&#xD;
             completing the protocol, including poor compliance during previous studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Satish R Raj, MD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unversity of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <results_first_submitted>March 16, 2021</results_first_submitted>
  <results_first_submitted_qc>April 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2021</results_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Satish Raj</investigator_full_name>
    <investigator_title>Professor; Medical Director, Calgary Autonomic Investigation &amp; Management Clinic</investigator_title>
  </responsible_party>
  <keyword>Tilt Table</keyword>
  <keyword>Compression</keyword>
  <keyword>Dysautonomia</keyword>
  <keyword>POTS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03484273/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a randomized cross-over trial. Participants were assigned to receive the 4 compressions interventions in a randomized order. There were a total of 24 potential sequence orders of the compression interventions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>4 Compression Interventions in Randomized Order</title>
          <description>Participants completed all 4 compression garment interventions in a random order. There were a total of 24 possible intervention orders. The 4 compression interventions were: Full Compression, Abdominal and Pelvic Compression, Lower Limb Compression and No Compression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32">This was a crossover trial. A total of 32 participants were enrolled in this study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30">This was a crossover trial. A total of 30 participants completed all 4 arms.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Equipment Malfunction</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Data excluded from analysis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Full Compression</title>
          <description>The LifeWrap compression garment will be fully secured with all straps.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Orthostatic Heart Rate (HR) Change</title>
        <description>The primary outcome measure will be the magnitude of HR change from supine to HUT (max HR between 5-10 min of HUT) for each study arm.</description>
        <time_frame>Maximum HR between 5-10min HUT MINUS the baseline (pre-tilt) HR</time_frame>
        <population>This was a crossover trial. A total of 30 participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Compression</title>
            <description>The LifeWrap compression garment will be fully secured with all straps.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
          </group>
          <group group_id="O2">
            <title>Abdominal and Pelvic Compression</title>
            <description>The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.</description>
          </group>
          <group group_id="O3">
            <title>Lower Limb Compression</title>
            <description>The Lifewrap compression garment calf and ankle straps only will be secured.</description>
          </group>
          <group group_id="O4">
            <title>No Compression</title>
            <description>None of the LifeWrap compression garment straps will be secured.</description>
          </group>
        </group_list>
        <measure>
          <title>Orthostatic Heart Rate (HR) Change</title>
          <description>The primary outcome measure will be the magnitude of HR change from supine to HUT (max HR between 5-10 min of HUT) for each study arm.</description>
          <population>This was a crossover trial. A total of 30 participants were analyzed.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="11"/>
                    <measurement group_id="O2" value="28" spread="11"/>
                    <measurement group_id="O3" value="34" spread="14"/>
                    <measurement group_id="O4" value="39" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated Measured ANOVA was used to compare the 4 compression garment configurations.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated Measures ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Upright Heart Rate</title>
        <description>The maximum heart rate during minutes 5-10 of each HUT. The maximum heart rate during each of the study arms will be compared.</description>
        <time_frame>During minutes 5-10 of the HUT</time_frame>
        <population>This was a crossover trial. A total of 30 participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Compression</title>
            <description>The LifeWrap compression garment will be fully secured with all straps.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
          </group>
          <group group_id="O2">
            <title>Abdominal and Pelvic Compression</title>
            <description>The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
          </group>
          <group group_id="O3">
            <title>Lower Limb Compression</title>
            <description>The Lifewrap compression garment calf and ankle straps only will be secured.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
          </group>
          <group group_id="O4">
            <title>No Compression</title>
            <description>None of the LifeWrap compression garment straps will be secured.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Upright Heart Rate</title>
          <description>The maximum heart rate during minutes 5-10 of each HUT. The maximum heart rate during each of the study arms will be compared.</description>
          <population>This was a crossover trial. A total of 30 participants were analyzed.</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" spread="14"/>
                    <measurement group_id="O2" value="97" spread="15"/>
                    <measurement group_id="O3" value="103" spread="16"/>
                    <measurement group_id="O4" value="109" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>]</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated Measures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Vanderbilt Orthostatic Symptom Score (VOSS) Symptom Rating</title>
        <description>Subjective symptom scoring as reported by participant during each study arm. The VOSS evaluates 9 symptoms on a 0 to 10 scale with 0 being no symptom to 10 being worst ever symptom. The total score ranges from 0-90, with a higher score being more severe symptoms.&#xD;
The 9 symptoms are mental clouding, blurred vision, shortness of breath, rapid heartbeat, tremulousness, chest discomfort, headache, lightheadedness, and nausea. The participant's VOSS score will be compared across the 4 arms of this study.&#xD;
The VOSS score has been previously used in multiple publications</description>
        <time_frame>After t=10 of the 10min HUT (or sooner if HUT has to be terminated early due to symptoms)</time_frame>
        <population>This was a crossover trial. A total of 30 participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Compression</title>
            <description>The LifeWrap compression garment will be fully secured with all straps.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
          </group>
          <group group_id="O2">
            <title>Abdominal and Pelvic Compression</title>
            <description>The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
          </group>
          <group group_id="O3">
            <title>Lower Limb Compression</title>
            <description>The Lifewrap compression garment calf and ankle straps only will be secured.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
          </group>
          <group group_id="O4">
            <title>No Compression</title>
            <description>None of the LifeWrap compression garment straps will be secured.</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Vanderbilt Orthostatic Symptom Score (VOSS) Symptom Rating</title>
          <description>Subjective symptom scoring as reported by participant during each study arm. The VOSS evaluates 9 symptoms on a 0 to 10 scale with 0 being no symptom to 10 being worst ever symptom. The total score ranges from 0-90, with a higher score being more severe symptoms.&#xD;
The 9 symptoms are mental clouding, blurred vision, shortness of breath, rapid heartbeat, tremulousness, chest discomfort, headache, lightheadedness, and nausea. The participant's VOSS score will be compared across the 4 arms of this study.&#xD;
The VOSS score has been previously used in multiple publications</description>
          <population>This was a crossover trial. A total of 30 participants were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="10"/>
                    <measurement group_id="O2" value="15" spread="12"/>
                    <measurement group_id="O3" value="22" spread="17"/>
                    <measurement group_id="O4" value="26" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated Measures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure (SBP)</title>
        <description>Change in continuous systolic blood pressure between supine and HUT during each study arm.</description>
        <time_frame>During the baseline before the HUT and the SBP correlating with the maximum HR during 5-10 min HUT, recorded at 1 min intervals.</time_frame>
        <population>This was a crossover trial. A total of 29 participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Compression</title>
            <description>The LifeWrap compression garment will be fully secured with all straps.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
          </group>
          <group group_id="O2">
            <title>Abdominal and Pelvic Compression</title>
            <description>The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.</description>
          </group>
          <group group_id="O3">
            <title>Lower Limb Compression</title>
            <description>The Lifewrap compression garment calf and ankle straps only will be secured.</description>
          </group>
          <group group_id="O4">
            <title>No Compression</title>
            <description>None of the LifeWrap compression garment straps will be secured.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (SBP)</title>
          <description>Change in continuous systolic blood pressure between supine and HUT during each study arm.</description>
          <population>This was a crossover trial. A total of 29 participants were analyzed.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="7"/>
                    <measurement group_id="O2" value="-7" spread="8"/>
                    <measurement group_id="O3" value="-10" spread="10"/>
                    <measurement group_id="O4" value="-10" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Repeated Measures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Stroke Volume</title>
        <description>Change in Stroke Volume from supine to HUT in each of the study arms.</description>
        <time_frame>During the baseline before the HUT and the SV correlating with the maximum HR during 5-10 min HUT, recorded at 1 min intervals.</time_frame>
        <population>This was a crossover trial. A total of 29 participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Compression</title>
            <description>The LifeWrap compression garment will be fully secured with all straps.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
          </group>
          <group group_id="O2">
            <title>Abdominal and Pelvic Compression</title>
            <description>The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.</description>
          </group>
          <group group_id="O3">
            <title>Lower Limb Compression</title>
            <description>The Lifewrap compression garment calf and ankle straps only will be secured.</description>
          </group>
          <group group_id="O4">
            <title>No Compression</title>
            <description>None of the LifeWrap compression garment straps will be secured.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Stroke Volume</title>
          <description>Change in Stroke Volume from supine to HUT in each of the study arms.</description>
          <population>This was a crossover trial. A total of 29 participants were analyzed.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22" spread="12"/>
                    <measurement group_id="O2" value="-22" spread="12"/>
                    <measurement group_id="O3" value="-33" spread="14"/>
                    <measurement group_id="O4" value="-34" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Repeated Measures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cardiac Output (CO)</title>
        <description>Change in Cardiac Output from supine to HUT in each of the study arms.</description>
        <time_frame>During the baseline before the HUT and the CO correlating with the maximum HR during 5-10 min HUT, recorded at 1 min intervals.</time_frame>
        <population>This was a crossover trial. A total of 29 participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Compression</title>
            <description>The LifeWrap compression garment will be fully secured with all straps.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
          </group>
          <group group_id="O2">
            <title>Abdominal and Pelvic Compression</title>
            <description>The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.</description>
          </group>
          <group group_id="O3">
            <title>Lower Limb Compression</title>
            <description>The Lifewrap compression garment calf and ankle straps only will be secured.</description>
          </group>
          <group group_id="O4">
            <title>No Compression</title>
            <description>None of the LifeWrap compression garment straps will be secured.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiac Output (CO)</title>
          <description>Change in Cardiac Output from supine to HUT in each of the study arms.</description>
          <population>This was a crossover trial. A total of 29 participants were analyzed.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.7"/>
                    <measurement group_id="O2" value="0.3" spread="0.7"/>
                    <measurement group_id="O3" value="-0.2" spread="1"/>
                    <measurement group_id="O4" value="-0.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Repeated Measures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systemic Vascular Resistance (SVR)</title>
        <description>Change in Systemic Vascular Resistance from supine to HUT in each of the study arms.</description>
        <time_frame>During the baseline before the HUT and the SVRcorrelating with the maximum HR during 5-10 min HUT, recorded at 1min intervals.</time_frame>
        <population>This was a crossover trial. A total of 29 participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Compression</title>
            <description>The LifeWrap compression garment will be fully secured with all straps.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
          </group>
          <group group_id="O2">
            <title>Abdominal and Pelvic Compression</title>
            <description>The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.</description>
          </group>
          <group group_id="O3">
            <title>Lower Limb Compression</title>
            <description>The Lifewrap compression garment calf and ankle straps only will be secured.</description>
          </group>
          <group group_id="O4">
            <title>No Compression</title>
            <description>None of the LifeWrap compression garment straps will be secured.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systemic Vascular Resistance (SVR)</title>
          <description>Change in Systemic Vascular Resistance from supine to HUT in each of the study arms.</description>
          <population>This was a crossover trial. A total of 29 participants were analyzed.</population>
          <units>dyne*s/cm^5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31" spread="132"/>
                    <measurement group_id="O2" value="-63" spread="152"/>
                    <measurement group_id="O3" value="-22" spread="157"/>
                    <measurement group_id="O4" value="4.7" spread="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Repeated Measures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cerebral Blood Flow Velocity (CBFV)</title>
        <description>Change in cerebral blood flow from supine to HUT in each of the study arms.</description>
        <time_frame>During the baseline before the HUT and the CBFV correlating with the maximum HR during 5-10 min HUT, recorded at 1 min intervals.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This was a half day study and there was no ongoing follow up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Full Compression</title>
          <description>The LifeWrap compression garment will be fully secured with all straps.&#xD;
LifeWrap Compression Garment: Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.</description>
        </group>
        <group group_id="E2">
          <title>Abdominal and Pelvic Compression</title>
          <description>The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.</description>
        </group>
        <group group_id="E3">
          <title>Lower Limb Compression</title>
          <description>The Lifewrap compression garment calf and ankle straps only will be secured.</description>
        </group>
        <group group_id="E4">
          <title>No Compression</title>
          <description>None of the LifeWrap compression garment straps will be secured.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a proof of principle study. The garment used is not one that a typical patient would use in their day to day lives. The use of &quot;real-world&quot; garments requires further testing.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Satish R. Raj</name_or_title>
      <organization>University of Calgary</organization>
      <phone>403-210-6152</phone>
      <email>satish.raj@ucalgary.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

